Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its ...

Schrödinger has entered a strategic agreement with BMS to integrate its AI-based co-scientist platform Bunsen into BMS’s research operations.

Premium Content is our new free subscription that provides access to deeper analysis, data-led features and exclusive reports.

Biologics CDMO AsymBio is set to secure $184m in funding from Asymchem Group, Hillhouse Qirui and other investors to support long-term growth.

Orexin receptor agonists signal potential across broader sleep disorders and even neurogenerative and rare diseases, and an upcoming approval decision could mark the beginning of an era with this ...

Set against the backdrop of a mixed Q2, Novo Nordisk is eyeing bolt-ons in favour of transformative acquisitions.

Scottish biopharmaceutical company Mironid has pocketed $46m in Series B funding raise to progress the development of its lead rare kidney disease candidate. The financing, which ...

CapVest Partners-backed Curium has agreed to acquire rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.

Phylo has collaborated with Chugai Pharmaceutical to implement the Biomni Lab platform within the latter’s drug discovery operations.

Through this merger, Supernus and Indivior will combine their commercial medicinal portfolios, which span CNS and opioid use disorders (OUDs).

The US FDA has granted breakthrough therapy designation to Lilly olomorasib as a potential treatment for adults with advanced pancreatic cancer who have already received at least one prior systemic ...

Pfizer emerged as a pharmaceutical powerhouse during the pandemic, but lower infection rates and narrower use cases mean its Covid-19 brands are impacting the company’s bottom l ...